Fenbendazole has real preclinical anti-cancer evidence — but zero completed human RCTs as of July 2026 and documented liver injury cases. This complete guide covers the Joe Tippens pembrolizumab confound, Korean n=78 study, 2 Phase I registered trials, the tubulin and glucose mechanism, a full 9-row evidence table, and what patients must tell their oncologist before using it.

Mebendazole shares a tubulin-inhibiting mechanism with established cancer drugs like Paclitaxel — which is why researchers have been investigating it in cancer contexts since the early 2000s. This factual guide covers what the laboratory research found, which actual human clinical trials have been registered, and why there is still a significant gap between research interest and clinical proof.